Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06811233 · ClinicalTrials.gov registry record · Phase 2
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
A Phase 2 study of Acute Myeloid Leukemia (AML), sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT06811233: Recruiting Phase 2 study of Acute Myeloid Leukemia (AML), sponsored by M.D. Anderson Cancer Center.
NCT06811233 is a Phase 2 study of Acute Myeloid Leukemia (AML) that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 140 participants, roughly in line with the 141-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06811233, a Phase 2 study of Acute Myeloid Leukemia (AML), is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Magnesium Sulfate
- DRUG DMSA
- DRUG Ca-EDTA
- DRUG Multivitamin
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-05-08 |
| Est. Completion | 2031-08-31 |
| Phase | Phase 2 |
What NCT06811233 shows while recruiting
NCT06811233 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 141-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target.
The record links to 1 condition, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 4 interventions - of which Magnesium Sulfate is the first listed.
NCT06811233 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06811233 about?
NCT06811233 is a clinical study titled "Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study". The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy...
What is the current status of trial NCT06811233?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-05-08. Estimated completion is 2031-08-31.
What conditions does trial NCT06811233 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT06811233?
The interventions under investigation include: Magnesium Sulfate (DRUG), DMSA (DRUG), Ca-EDTA (DRUG), Multivitamin (DRUG).
Who is sponsoring clinical trial NCT06811233?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06811233 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia (AML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06811233's enrollment target sits among peer trials
140 7th of 29 higher than 23 of 29 other Acute Myeloid Leukemia (AML) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia (AML) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ivosidenib as Post-HSCT Maintenance for AML
RECRUITING · Phase 2
-
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
RECRUITING · Phase 2
-
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 2
-
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI